Philip Haywood is a clinician and academic with extensive cross disciplinary experience from medical, policy and economic perspectives. He worked for over a decade in the emergency department at Newcastle’s Calvary Mater Hospital. His PhD was in the use of administrative data to support an outcome based funding model.
As an economist, Phil has investigated the integration of hospital level cancer registries for NSW Health. At the OECD he researched how different countries have approached the introduction of new technologies. In Australia, Phil was involved in producing NHMRC guidelines for lung cancer and economic evaluations. Phil has been involved in trial design and evaluation of new technologies in health care.
His focus is on producing economic evidence for real world decision making with an emphasis on the introduction of new technologies. He now serves on the protocol advisory sub-committee for the Medical Services Advisory Committee. He has acted as a clinical advisor to the CHERE economic evaluation team for a decade.
Can supervise: YES
Parkinson, B, Gumbie, M, Cutler, H, Gauld, N, Mumford, V & Haywood, P 2019, 'Cost-effectiveness of reclassifying triptans in Australia: Application of an economic evaluation approach to regulatory decisions', Value in Health, vol. 22, no. 3, pp. 293-302.View/Download from: Publisher's site
Saing, S, Haywood, P, van der Linden, N, Manipis, K, Meshcheriakova, E & Goodall, S 2019, 'Real-World Cost Effectiveness of Mandatory Folic Acid Fortification of Bread-Making Flour in Australia.', Applied health economics and health policy, vol. 17, no. 2, pp. 243-254.View/Download from: Publisher's site
BACKGROUND:In 2009, mandatory folic acid fortification of bread-making flour was introduced in Australia to reduce the birth prevalence of preventable neural tube defects (NTDs) such as spina bifida. Before the introduction of the policy, modelling predicted a reduction of 14-49 NTDs each year. OBJECTIVE:Using real-world data, this study provides the first ex-post evaluation of the cost effectiveness of mandatory folic acid fortification of bread-making flour in Australia. METHODS:We developed a decision tree model to compare different fortification strategies and used registry data to quantify the change in NTD rates due to the policy. We adopted a societal perspective that included costs to industry and government as well as healthcare and broader societal costs. RESULTS:We found 32 fewer NTDs per year in the post-mandatory folic acid fortification period. Mandatory folic acid fortification improved health outcomes and was highly cost effective because of the low intervention cost. The policy demonstrated improved equity in outcomes, particularly in birth prevalence of NTDs in births from teenage and indigenous mothers. CONCLUSIONS:This study calculated the value of mandatory folic acid fortification using real-world registry data and demonstrated that the attained benefit was comparable to the modelled expected benefits. Mandatory folic acid fortification (in addition to policies including advice on supplementation and education) improved equity in certain populations and was effective and highly cost effective for the Australian population.
Saing, S, Haywood, P, Duncan, J, Ma, N, Cameron, A & Goodall, S 2018, 'Cost-effective imaging for resectability of liver lesions in colorectal cancer: An economic decision model', ANZ Journal of Surgery, vol. 88, no. 6, pp. E507-E511.View/Download from: UTS OPUS or Publisher's site
Longden, T, Wong, C, Haywood, P, Hall, J & Van Gool, K 2018, 'The prevalence of persistence and related health status: An analysis of persistently high healthcare costs in the short term and medium term', Social Science and Medicine, vol. 211, pp. 147-156.View/Download from: UTS OPUS or Publisher's site
Cronin, PA, Kirkbidge, B, Bang, A, Smith, D, Parkinson, B & Haywood, P 2017, 'Long-term health care costs for patients with prostate cancer: A population-wide longitudinal study in New South Wales Australia', Asia Pacific Journal of Clinical Oncology, vol. 13, no. 3, pp. 160-171.View/Download from: UTS OPUS or Publisher's site
Daniels, B, Lord, S, Kiely, B, Houssami, N, Lu, C, Ward, R, Haywood, P & Pearson, S 2017, 'Use and outcomes of targeted therapies in early and metastatic HER2–positive breast cancer in Australia: Protocol detailing observations in a whole of population cohort', BMJ Open, vol. 7, pp. 1-12.View/Download from: UTS OPUS or Publisher's site
Background The management of human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC) has changed dramatically with the introduction and widespread use of HER2-targeted therapies. However, there is relatively limited real-world information on patterns of use, effectiveness and safety in whole of population cohorts. The research programme detailed in this protocol will generate evidence on the prescribing patterns, safety monitoring and outcomes of patients with BC treated with HER2-targeted therapies in Australia.
Methods/design Our ongoing research programme will involve a series of retrospective cohort studies that include every patient accessing Commonwealth-funded HER2-targeted therapies for the treatment of early BC and advanced BC in Australia. At the time of writing, our cohorts consist of 11 406 patients with early BC and 5631 with advanced BC who accessed trastuzumab and lapatinib between 2001 and 2014. Pertuzumab and trastuzumab emtansine were publicly funded for metastatic BC in 2015, and future data updates will include patients accessing these medicines. We will use dispensing claims for cancer and other medicines, medical service claims and demographics data for each patient accessing HER2-targeted therapies to undertake this research.
Ethics and dissemination Ethics approval has been granted by the Population Health Service Research Ethics Committee and data access approval has been granted by the Australian Department of Human Services (DHS) External Review Evaluation Committee. Our findings will be reported in peer-reviewed publications, conference presentations and policy forums. By providing detailed information on the use and outcomes associated with HER2-targeted therapies in a national cohort treated in routine clinical care, our research programme will better inform clinicians and patients about the real-world use of these treatments and will assist third-party payers to better understand the use and economic costs of t...
Pearce, AM, Haas, M, Viney, R, Pearson, S-A, Haywood, P, Brown, C & Ward, R 2017, 'Incidence and severity of self-reported chemotherapy side effects in routine care: A prospective cohort study', PLoS ONE, vol. 12, no. 10.View/Download from: UTS OPUS or Publisher's site
Pearce, A, Haas, M, Viney, R, Haywood, P, Pearson, S-A, van Gool, K, Srasuebkul, P & Ward, R 2015, 'Can administrative data be used to measure chemotherapy side effects?', EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, vol. 15, no. 2, pp. 215-222.View/Download from: Publisher's site
Ward, RL, Laaksonen, MA, van Gool, K, Pearson, S-A, Daniels, B, Bastick, P, Norman, R, Hou, C, Haywood, P & Haas, M 2015, 'Cost of cancer care for patients undergoing chemotherapy: The Elements of Cancer Care study', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, vol. 11, no. 2, pp. 178-+.View/Download from: Publisher's site
Pearce, AM, Van Gool, K, Haywood, P & Haas, MR 2014, 'Delays in access to affordable medicines: putting policy into perspective - Authors' response', Australian Health Review, vol. 38, no. 1, pp. 16-17.
Haywood, P, de Raad, J, Van Gool, K, Haas, MR, Gallego, G, Pearson, S, Faedo, M & Ward, RL 2012, 'Title:Chemotherapy administration: modelling the costs of alternative protocols..', Pharmacoeconomics, vol. 30, no. 12, pp. 1173-1186.View/Download from: UTS OPUS or Publisher's site
Pearce, AM, Van Gool, K, Haywood, P & Haas, MR 2012, 'Delays in access to affordable medicines: putting policy into perspective', Australian Health Review, vol. 36, no. 4, pp. 412-418.View/Download from: UTS OPUS or Publisher's site
To save costs, the Australian Government recently deferred approval of seven new medicines recommended by the Pharmaceutical Benefits Advisory Committee (PBAC) for up to 7 months.Objectives: The aim of this research is to examine the timelines of PBAC applications following approval by the Therapeutic Goods Administration (TGA), allowing the recent Cabinet delays to be considered in the context of the overall medicines approval process. Methods. All new chemical entities and products for new indications approved in 2004 by the Australian Drug Evaluation Committee (ADEC) were identified. Outcomes of PBAC meetings from 2004 to 2010 were then searched to identify if and when these products were reviewed by PBAC. Results: ADEC recommended 63 eligible products for registration in 2004. Of the 113 submissions made to PBAC for these products, 66 were successful. Only 43% of the products were submitted to PBAC within 2 years, with an average 17-month delay from TGA approval of a product to consideration by the PBAC. Conclusions: Cabinet decisions to defer listing of new medicines delays access to new treatments. This occurred in addition to other longer delays, earlier in the approval process for medicines, resulting in a significant impact on the overall timeliness of listing.
de Raad, J, Van Gool, K, Haas, MR, Haywood, P, Faedo, M, Gallego, G, Pearson, S & Ward, R 2010, 'Nursing takes time: Workload associated with administering cancer protocols', Clinical Journal of Oncology Nursing, vol. 14, no. 6, pp. 735-741.View/Download from: UTS OPUS or Publisher's site
New medicines and therapeutic combinations are tested and marketed every year. Healthcare decision makers have to make explicit choices about adopting new treatments and deal with the resource consequences of their choices. The aim of this article is to examine the nursing workload of administering alternative chemotherapy protocols as a driver of costs. Data collection (focus groups with chemotherapy nurses and a survey of nurse unit managers) was conducted to ascertain the time required to undertake chemotherapy-related tasks and the sources of variability in six chemotherapy centers in New South Wales, Australia. Four task types (patient education, patient assessment, administration, and patient communication) were identified as being associated with administering chemotherapy. On average, patient education required 48 minutes during the first visit and 18.5 minutes thereafter, patient assessment took 20.3 minutes, administration averaged 23 minutes, and patient communication required 24.2 minutes. Each center treated an average of 14 patients per day. Each patient received 3.3 hours of staff time (1.7 hours of direct contact time and 1.6 hours of noncontact time). The result of this research will allow healthcare decision makers and evaluators to predict the amount of nursing time required to administer chemotherapy based on the characteristics of a wide range of chemotherapy protocols.
Anderson, R, Haywood, P, Usherwood, T, Haas, MR & Hall, JP 2005, 'Alternatives to for-profit corporatisation: The view from general practice', Australian Journal of Primary Health, vol. 11, no. 2, pp. 78-86.View/Download from: UTS OPUS
Bridges, JF & Haywood, P 2003, 'Theory versus empiricism in health economics: as analysis of the past 20 years', European Journal of Health Economics, vol. 4, no. 2, pp. 90-95.View/Download from: UTS OPUS or Publisher's site
Gibson, P, Powell, H, Coughlan, J, Wilson, A, Abramson, M, Haywood, P, Bauman, A, Hensley, M & Walters, E 2002, 'Self-management education and regular practitioner review for adults with asthma', Cochrane Database of Systematic Reviews, no. Issue 3.View/Download from: Publisher's site
Richardson, M 2002, 'Economic efficiency in law and economies', ECONOMIC RECORD, vol. 78, no. 241, pp. 232-233.
Van Gool, K, Lancsar, E, Viney, RC, Hall, JP & Haywood, P 2002, 'Diagnosis and prognosis of Australia's health information for evidence based policy', Journal of Health Services Research & Policy, vol. 7, no. 1, pp. 40-45.View/Download from: UTS OPUS or Publisher's site
Richardson, M, Quiggin, J, Qiu, LD, Haywood, P, Peacock, A, Cornish, S, Hamilton, G, Adam, CM, Cavoli, T & Thornton, SR 2002, 'Reviews', The Economic Record, vol. 78, pp. 232-247.
Haywood, P 2018, 'Real world costs of increasing complexity of cancer', ISPOR Asia Pacific 2018, Tokyo, Japan.
Manipis, K, Mulhern, B, Pearce, A, Haywood, P, Viney, R & Goodall, S 2018, 'Estimating the willingness to pay to avoid the impacts of foodborne illnesses: A Discrete Choice Experiment', ISPOR Asia Pacific 2018, Tokyo, Japan.
Parkinson, B, Gumbie, M, Cutler, H, Gauld, N, Mumford, V & Haywood, P 2018, 'Cost-effectiveness of reclassifying triptans in Australia', ISPOR Asia Pacific, Tokyo, Japan.
Manipis, K, Mulhern, B, Haywood, P, Viney, R & Goodall, S 2017, 'Estimating the impact of paid and unpaid sick leave on preferences for avoiding the negative impacts of foodborne illnesses [conference presentation]', 39th Annual Australian Health Economics Society Conference, Sydney.
Saing, S., Haywood, P. & Goodall, S. 2016, 'Cost effectiveness of contrast-enhanced liver MRI in the characterisation of suspected liver lesions in patients with colorectal cancer', ISPOR Asia-Pacific Conference, Singapore.
Saing, S, Haywood, P & Goodall, S 2016, 'Cost effectiveness of contrast-enhanced liver MRI in the characterisation of suspected liver lesions in patients with colorectal cancer', ISPOR Asia-Pacific Conference, Singapore.
Longden, T, Wong, CY, Haywood, P, Hall, J & van Gool, K 2016, 'A question of persistence and related health states: an analysis of persistently high healthcare costs in the short term and long term', Australian Health Economics Society Conference, Fremantle, Australia.
Saing, S, Haywood, P & Goodall, S 2016, 'Economic evaluation of contrast-enhanced liver MRI in the characterisation of suspected liver lesions', ISPOR Australia Chapter, Contemporary Economic Modelling: State of the Art, Sydney.
Haywood, P 2015, 'Do we need a new system to price oncology pharmaceuticals?', Cancer Institute NSW Innovations Conference, Sydney.
Pearce, AM, Haas, M, Viney, R, Pearson, S, Haywood, P & Ward, R 2014, 'Rates of chemotherapy adverse event in clinical practice: results from a prospective cohort study', World Cancer Congress, Melbourne.View/Download from: UTS OPUS
Faedo, M, Pearson, S, Bastick, P, Van Gool, K, Haywood, P, Haas, MR & Ward, R 2009, 'Elements of Care Study: Tracking resource utilisation and costs in a cohort of NSW cancer patients', 6th Health Services and Policy Conference 2009, Brisbane.
Haywood, P, Goodall, S, Chinchen, E, Haas, M, Manipis, K, Meshcheriakova, O, Saing, S & van der Linden, N COAG Health Council 2017, The effectiveness and cost-effectiveness of mandatory folic acid and iodine fortification. A report for the Australian Health Ministers' Advisory Council, Adelaide.View/Download from: UTS OPUS
De Abreu Lourenco, R, Haywood, P, Parkinson, B, van Gool, K & Viney, R CHERE 2015, The economic implications of a genomically guided approach to cancer: A report by the Centre for Health Economics Research and Evaluation for the Cancer Council, Sydney.
This report examines how genomically based approaches may also alter the way that new technologies are funded and adopted in the health care system. In particular, how they challenge the routine pathways by which technologies are diffused into routine practice. The report also focuses on how genomically guided technologies challenge current coverage decisions. It examines the economic evidence-base for assessing the cost and benefits of such technologies. In doing so, the report highlights the current limitations in this field of research as identified through a systematic review of recommendations made by Australian policy-makers, as well as through a review of the literature. This analysis is then used to develop a framework for economic evaluations with special reference to genomically based technologies. Finally, the report also identifies a number of key policy challenges for the efficient diffusion of genomically guided cancer care into the Australian health care system.
Longden, T, Wong, C, Haywood, P, Hall, J & Van Gool, K 2018, 'The importance of comorbidity and multimorbidity in determining health care costs: An analysis of the cost amplifications associated with morbidity interaction variables. CHERE Working Paper 2018/01'.View/Download from: UTS OPUS